Commitments and Contingencies (Details) - USD ($)				1 Months Ended		3 Months Ended	6 Months Ended
	Jul. 08, 2024	Nov. 29, 2023	Oct. 18, 2023	Nov. 29, 2023	Mar. 31, 2023	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023
Commitments and Contingencies [Line Items]
Insurance reimbursement amount					$ 1,250,000	$ 0		$ 1,250,000
Several liability arrangement			$ 14,684,833
Net sales of epoladerm			5.00%
Net sales of envelta			7.50%
Trade amount		$ 6,700,000	$ 13,400,000
Development of epoladerm				18 months 27 days
Proffered documents (in Shares)		1,182		1,182
Several liability		$ 28,382
Litigation settlement							$ 3,500,000
Royalties annual net sales percentage							6.00%
Initial payment							$ 3,500,000
Accrued litigation							2,500,000		$ 6,000,000
Accrual litigation							2,500,000
Bankruptcy Court [Member]
Commitments and Contingencies [Line Items]
Litigation settlement							6,000,000
Minimum [Member]
Commitments and Contingencies [Line Items]
Net sales of probudur			8.00%
Royalty rate		1.00%
Maximum [Member]
Commitments and Contingencies [Line Items]
Net sales of probudur			11.00%
Royalty rate		3.00%
Misuse of Scilex [Member]
Commitments and Contingencies [Line Items]
Trade amount			$ 1,300,000
Subsequent Event [Member]
Commitments and Contingencies [Line Items]
Litigation settlement	$ 2,500,000
Mr Mack and Virpax [Member]
Commitments and Contingencies [Line Items]
Trade amount			$ 6,700,000
Estimated separation expense.							711,000		$ 711,000
Litigation [Member]
Commitments and Contingencies [Line Items]
Initial payment							$ 3,500,000